[go: up one dir, main page]

MX350224B - Formulaciones parasiticidas transdermicas. - Google Patents

Formulaciones parasiticidas transdermicas.

Info

Publication number
MX350224B
MX350224B MX2015007824A MX2015007824A MX350224B MX 350224 B MX350224 B MX 350224B MX 2015007824 A MX2015007824 A MX 2015007824A MX 2015007824 A MX2015007824 A MX 2015007824A MX 350224 B MX350224 B MX 350224B
Authority
MX
Mexico
Prior art keywords
formulation
transdermal
transdermal parasiticidal
solution including
formulations
Prior art date
Application number
MX2015007824A
Other languages
English (en)
Other versions
MX2015007824A (es
Inventor
Yeritsyan Karen
Original Assignee
Donaghys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50978785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX350224(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Donaghys Ltd filed Critical Donaghys Ltd
Publication of MX2015007824A publication Critical patent/MX2015007824A/es
Publication of MX350224B publication Critical patent/MX350224B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N35/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical
    • A01N35/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical containing aliphatically bound aldehyde or keto groups, or thio analogues thereof; Derivatives thereof, e.g. acetals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pest Control & Pesticides (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se describen formulaciones parasiticidas transdérmicas y los métodos de tratamiento y uso, en donde la formulación no sólo es capaz de suministrar un agente o agentes a través de la capa cutánea, sino que también es capaz de hacerlo a través de la lana, suciedad y/o una capa de sebo sobre la piel si están presentes estas capas. La formulación parasiticida transdérmica puede ser una solución que incluye una cantidad terapéuticamente efectiva de un agente antihelmíntico con levamisol disuelto en una solución que incluye miristato de isopropilo y D-limoneno. Esta formulación base es bastante compatible con otros compuestos y se pueden agregar a esta formulación otros diversos activos.
MX2015007824A 2012-12-18 2013-12-16 Formulaciones parasiticidas transdermicas. MX350224B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ60484812 2012-12-18
NZ60693813 2013-02-12
PCT/NZ2013/000235 WO2014098619A1 (en) 2012-12-18 2013-12-16 Transdermal parasiticidal formulations

Publications (2)

Publication Number Publication Date
MX2015007824A MX2015007824A (es) 2016-01-14
MX350224B true MX350224B (es) 2017-08-30

Family

ID=50978785

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007824A MX350224B (es) 2012-12-18 2013-12-16 Formulaciones parasiticidas transdermicas.

Country Status (11)

Country Link
US (2) US9649299B2 (es)
EP (1) EP2934522B1 (es)
CN (2) CN110507606A (es)
AU (6) AU2013364520A1 (es)
BR (1) BR112015014266B1 (es)
CA (1) CA2895038C (es)
CL (1) CL2015001748A1 (es)
MX (1) MX350224B (es)
RU (1) RU2660357C2 (es)
WO (1) WO2014098619A1 (es)
ZA (1) ZA201504370B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350224B (es) 2012-12-18 2017-08-30 Donaghys Ltd Formulaciones parasiticidas transdermicas.
BR112015020707B1 (pt) * 2013-02-27 2022-09-13 Laurie Robert Batt Composição transdérmica anidra e método de fabricação da mesma
CN108472286B (zh) * 2016-04-15 2022-03-01 江苏龙灯化学有限公司 一种用于杀灭动物体外寄生虫的药物组合物及其制备方法和用途
GB2552952B (en) * 2016-08-12 2020-03-04 Norbrook Lab Ltd Moxidectin topical liquid formulations
WO2018038623A1 (en) * 2016-08-23 2018-03-01 Donaghys Limited Improvements in parasite treatments
BR112022000767A2 (pt) 2019-07-16 2022-03-15 Donaghys Ltd Sistema de solvente transdérmico e métodos de uso

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2614841A1 (de) * 1976-04-06 1977-10-20 Bayer Ag Neue pour-on-formulierungen von anthelmintika
DE3241113A1 (de) * 1982-11-06 1984-05-10 Bayer Ag, 5090 Leverkusen Vakzinen mit zuschlagstoffen
GB8613914D0 (en) 1986-06-07 1986-07-09 Coopers Animal Health Liquid formulations
NZ508969A (en) 1999-06-04 2002-12-20 Nufarm Ltd Pesticidal emulsion containing levamisole in the aqueous phase and a macrocyclic lactone anthelmintic in the organic phase
US6933318B1 (en) * 1999-08-12 2005-08-23 Eli Lilly And Company Topical organic ectoparasiticidal formulations
NZ507445A (en) 2000-10-10 2003-03-28 Wyeth Corp Moxidectrin and praziquantel oral drench
AUPR510001A0 (en) * 2001-05-18 2001-06-14 Jupitar Pty Ltd Formulation and method
NZ517227A (en) 2002-02-15 2003-04-29 Ashmont Holdings Ltd Sheep pour-on formulation comprising avermectins or milbemycins, a penetrating agent and a solvent
HUE032009T2 (en) * 2003-04-04 2017-09-28 Merial Inc Veterinary preparations for topical veterinary use
DE10358525A1 (de) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
KR100784485B1 (ko) * 2006-01-18 2007-12-11 한국과학기술연구원 생분해성 온도 감응성 폴리포스파젠계 하이드로젤, 그의제조방법 및 그의 용도
TWI430995B (zh) * 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
BRPI0910269B1 (pt) * 2008-03-19 2020-10-06 Tyratech, Inc Composições e métodos de controle de praga
CN101703776B (zh) * 2009-09-28 2012-07-11 洛阳惠中兽药有限公司 一种抗感染剂长效注射液的制备方法
CN101670103A (zh) * 2009-09-30 2010-03-17 西北农林科技大学 一种复方人参总皂甙和左旋咪唑纳米乳佐剂及其制备方法
CN102614173A (zh) * 2012-03-07 2012-08-01 西北农林科技大学 一种复方美贝霉素肟纳米乳抗寄生虫药物及其制备方法
MX350224B (es) 2012-12-18 2017-08-30 Donaghys Ltd Formulaciones parasiticidas transdermicas.

Also Published As

Publication number Publication date
ZA201504370B (en) 2017-11-29
CN104994852A (zh) 2015-10-21
CL2015001748A1 (es) 2015-11-13
US9649299B2 (en) 2017-05-16
AU2024203462A1 (en) 2024-06-13
CA2895038A1 (en) 2014-06-26
AU2018208642A1 (en) 2018-08-09
BR112015014266A2 (pt) 2017-07-11
EP2934522A1 (en) 2015-10-28
US20170312256A1 (en) 2017-11-02
RU2015122162A (ru) 2017-01-26
RU2660357C2 (ru) 2018-07-05
AU2013364520A1 (en) 2015-07-02
AU2022201140A1 (en) 2022-03-17
US20150283119A1 (en) 2015-10-08
EP2934522A4 (en) 2016-07-20
CA2895038C (en) 2020-11-24
MX2015007824A (es) 2016-01-14
CN110507606A (zh) 2019-11-29
EP2934522B1 (en) 2018-08-15
BR112015014266B1 (pt) 2021-01-26
WO2014098619A1 (en) 2014-06-26
AU2017201224A1 (en) 2017-03-09
AU2017201224B2 (en) 2018-04-26
AU2020204198A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
MX2015007824A (es) Formulaciones parasiticidas transdermicas.
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
IN2014CN02128A (es)
AR064268A1 (es) Sistema terapeutico transdermico para administracion del principio activo buprenorfina
CR20170097A (es) Compuestos terapéuticamente activos y sus métodos de uso (divisional)
BR112016002287A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
BR112014016805A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
CL2012002317A1 (es) Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras.
CL2012000446A1 (es) Uso de una formulación vesicular tópica que comprende uno o más fosfolípidos y uno o más tensoactivos en una razón molar de 1:1 a 25:1 de fosfolípidos a tensoactivos, para el tratamiento de trastornos dermatosos inflamatorios.
AR097556A1 (es) Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas
MX2012007933A (es) Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso.
CR20140567A (es) Formulaciones y métodos para la administración vaginal de antiprogestinas
BR112012020731A2 (pt) pastilhas gelatinosas suaves com nicotina.
MX2009012273A (es) Dispositivos de suministro transd?rmico que aseguran la liberaci?n mejorada de un principio activo a trav?s de una interfaz biol?gica.
CL2015001652A1 (es) Compuestos derivados de 4-(bifenil-3-il)-7h-imidazo[4,5-c]piridazina, moduladores de la actividad del receptor gabaa; composicion farmaceutica que los comprende; combinacion que los comprende junto a un segundo agente farmaceuticamente activo; metodo de tratamiento del dolor; y su uso para el tratamiento del dolor.
EA201300704A1 (ru) Трансдермальная терапевтическая система для введения активного вещества
UA112549C2 (uk) Частинки на основі поліакрилату, що містять активну сполуку
CL2014002706A1 (es) Formulaciones vesiculares que comprenden un fosfolipido y un agente tensoactivo y el uso en el tratamiento del dolor o movilidad reducida de una articulación.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
PE20142358A1 (es) Nuevas formas y sales de un dihidropirrolo[1,2-c]imidazolilo, inhibidor de la aldosterona sintasa o aromatasa
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
BR112014013878A2 (pt) emplastro
PH12016500142A1 (en) Vesicles
AR083095A1 (es) Cocristal de aprepitant l-prolina y composicion farmaceutica

Legal Events

Date Code Title Description
FG Grant or registration